Christopher Gottschalk, MD, FAHS

• Deepak Cyril Dsouza
• Edward Perry
• Francesc Lopez-Giraldez
• Murat Gunel
• R Peter Manes

Brain Mapping; Cluster Headache; Migraine Disorders; Neurochemistry; Cortical Spreading Depression; Trigeminal Neuralgia; Headache Disorders, Primary; Headache Disorders, Secondary; Trigeminal Autonomic Cephalalgias

Chronic Diseases; Health Care Management; Substance Use, Addiction; Child/Adolescent Health; Health Equity, Disparities, Social Determinants and Justice

• Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trialSchindler E, Sewell R, Gottschalk C, Luddy C, Flynn L, Zhu Y, Lindsey H, Pittman B, Cozzi N, D'Souza D. Exploratory investigation of a patient‐informed low‐dose psilocybin pulse regimen in the suppression of cluster headache: Results from a randomized, double‐blind, placebo‐controlled trial. Headache The Journal Of Head And Face Pain 2022, 62: 1383-1394. PMID: 36416492, DOI: 10.1111/head.14420.
• Migraine—Not Just a Numbers GameKopel D, Gottschalk C. Migraine—Not Just a Numbers Game. Neurology 2022, 100: 357-358. PMID: 36396450, DOI: 10.1212/wnl.0000000000201566.
• The Epidemiology of Primary Headache DisordersKopel D, Gottschalk C. The Epidemiology of Primary Headache Disorders. Seminars In Neurology 2022, 42: 449-458. PMID: 36104164, DOI: 10.1055/a-1942-6823.
• The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature reviewGottschalk C, Buse DC, Marmura MJ, Torphy B, Pavlovic JM, Dumas PK, Lalvani N, Blumenfeld A. The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Therapeutic Advances In Neurological Disorders 2022, 15: 17562864221095902. PMID: 35662957, PMCID: PMC9160905, DOI: 10.1177/17562864221095902.
• The importance of an early onset of migraine preventive disease control: A roundtable discussionGottschalk C, Basu A, Blumenfeld A, Torphy B, Marmura M, Pavlovic J, Dumas P, Lalvani N, Buse D. The importance of an early onset of migraine preventive disease control: A roundtable discussion. Cephalalgia Reports 2022, 5: 25158163221134593. DOI: 10.1177/25158163221134593.
• Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare populationTorabi SJ, Kasle DA, Savoca EL, Gottschalk CH, Manes RP. Characterizing the providers of and reimbursement for chronic migraine chemodenervation among the Medicare population. Headache The Journal Of Head And Face Pain 2020, 61: 373-384. PMID: 33337542, DOI: 10.1111/head.14040.
• Exploratory Controlled Study of the Migraine-Suppressing Effects of PsilocybinSchindler EAD, Sewell RA, Gottschalk CH, Luddy C, Flynn LT, Lindsey H, Pittman BP, Cozzi NV, D'Souza D. Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics 2020, 18: 534-543. PMID: 33184743, PMCID: PMC8116458, DOI: 10.1007/s13311-020-00962-y.
• Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After DosingDodick DW, Gottschalk C, Cady R, Hirman J, Smith J, Snapinn S. Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing. Headache The Journal Of Head And Face Pain 2020, 60: 2220-2231. PMID: 33165938, PMCID: PMC7756794, DOI: 10.1111/head.14007.
• Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal NeuralgiaDong W, Jin SC, Allocco A, Zeng X, Sheth AH, Panchagnula S, Castonguay A, Lorenzo LÉ, Islam B, Brindle G, Bachand K, Hu J, Sularz A, Gaillard J, Choi J, Dunbar A, Nelson-Williams C, Kiziltug E, Furey CG, Conine S, Duy PQ, Kundishora AJ, Loring E, Li B, Lu Q, Zhou G, Liu W, Li X, Sierant MC, Mane S, Castaldi C, López-Giráldez F, Knight JR, Sekula RF, Simard JM, Eskandar EN, Gottschalk C, Moliterno J, Günel M, Gerrard JL, Dib-Hajj S, Waxman SG, Barker FG, Alper SL, Chahine M, Haider S, De Koninck Y, Lifton RP, Kahle KT. Exome Sequencing Implicates Impaired GABA Signaling and Neuronal Ion Transport in Trigeminal Neuralgia. IScience 2020, 23: 101552. PMID: 33083721, PMCID: PMC7554653, DOI: 10.1016/j.isci.2020.101552.
• The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort.Schwedt TJ, Digre K, Tepper SJ, Spare NM, Ailani J, Birlea M, Burish M, Mechtler L, Gottschalk C, Quinn AM, McGillicuddy L, Bance L, Dumkrieger G, Chong CD, Dodick DW. The American Registry for Migraine Research: Research Methods and Baseline Data for an Initial Patient Cohort. Headache 2020, 60: 337-347. PMID: 31755111, DOI: 10.1111/head.13688.
• Cognitive Biases & Errors in Headache MedicineGottschalk CH. Cognitive Biases & Errors in Headache Medicine. Headache The Journal Of Head And Face Pain 2019, 59: 1863-1870. PMID: 31680238, DOI: 10.1111/head.13686.
• Beta-Blockers for Migraine Prevention: a Review ArticleDanesh A, Gottschalk PCH. Beta-Blockers for Migraine Prevention: a Review Article. Current Treatment Options In Neurology 2019, 21: 20. PMID: 30903383, DOI: 10.1007/s11940-019-0556-3.
• Abstract TP396: Distinguishing Characteristics of Headache in Non-Traumatic Subarachnoid HemorrhageMac Grory B, Vu L, Marcolini E, Gottschalk C, Greer D. Abstract TP396: Distinguishing Characteristics of Headache in Non-Traumatic Subarachnoid Hemorrhage. Stroke 2018, 49 DOI: 10.1161/str.49.suppl_1.tp396.
• Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use SurveySchindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.
• Treatment of Chronic Migraine with Focus on Botulinum NeurotoxinsSchaefer SM, Gottschalk CH, Jabbari B. Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins. Toxins 2015, 7: 2615-2628. PMID: 26184313, PMCID: PMC4516932, DOI: 10.3390/toxins7072615.
• Telcagepant—almost gone, but not to be forgotten (invited editorial related to Ho et al., 2015)Gottschalk PC. Telcagepant—almost gone, but not to be forgotten (invited editorial related to Ho et al., 2015). Cephalalgia 2015, 36: 103-105. PMID: 25944815, DOI: 10.1177/0333102415584311.
• Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette SmokingStaley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow P, Verhoeff NP, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking. JAMA Psychiatry 2005, 62: 877-888. PMID: 16061765, DOI: 10.1001/archpsyc.62.8.877.
• Cognitive Function and Cerebral Perfusion During Cocaine AbstinenceGottschalk C, Beauvais J, Hart R, Kosten T. Cognitive Function and Cerebral Perfusion During Cocaine Abstinence. American Journal Of Psychiatry 2001, 158: 540-545. PMID: 11282686, DOI: 10.1176/appi.ajp.158.4.540.
• Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary reportJacobsen L, Giedd J, Kreek M, Gottschalk C, Kosten T. Quantitative medial temporal lobe brain morphology and hypothalamic-pituitary-adrenal axis function in cocaine dependence: a preliminary report. Drug And Alcohol Dependence 2001, 62: 49-56. PMID: 11173167, DOI: 10.1016/s0376-8716(00)00159-9.
• Functional Magnetic Resonance Imaging of Cocaine CravingWexler BE, Gottschalk CH, Fulbright RK, Prohovnik I, Lacadie CM, Rounsaville BJ, Gore JC. Functional Magnetic Resonance Imaging of Cocaine Craving. American Journal Of Psychiatry 2001, 158: 86-95. PMID: 11136638, DOI: 10.1176/appi.ajp.158.1.86.